![](https://www.vasculitisfoundation.org/wp-content/uploads/2023/10/Screenshot-2023-10-25-at-11.25.11-AM.png)
Amgen Successfully Completes Acquisition of ChemoCentryx
Blog TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN)